 LOS ANGELES--BUSINESS WIRE--CytRx Corporation OTCQB: CYTR CytRx, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme AS NASDAQ: ORPH Orphazyme announced it has received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treat 